title: Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics.
abstract: A study in dogs demonstrated that the commercially available formulation of IV levetiracetam (LEV) could be given safely IM and was quickly and completely absorbed. In this crossover study, 5 women and 5 men were given IM and IV LEV. This study demonstrates that administration of 5ml (500mg) IM LEV is well tolerated and its bioavailability is equivalent to an IV injection.
authors: University of Minnesota, Minneapolis, MN 55455, United States; MINCEP Epilepsy Care, Minneapolis, MN 55416, United States. leppi001@umn.edu
authors: Ilo E
authors: IE
authors: Leppik
authors: Varun
authors: V
authors: Goel
authors: John
authors: J
authors: Rarick
authors: Donald R
authors: DR
authors: Nixdorf
authors: James C
authors: JC
authors: Cloyd
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement / Q000379:methods; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: D000077287:Levetiracetam; D010889:Piracetam